Brevan Howard Capital Management’s Altimmune ALT Stock Holding History

Brevan Howard Capital Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$241K	Sell	78,403 -35,725	-31%	-$152K	﹤0.01%	1785
2025 Q4	$412K	Sell	114,128 -108,814	-49%	-$474K	﹤0.01%	1203
2025 Q3	$840K	Buy	222,942 +89,733	+67%	+$346K	﹤0.01%	984
2025 Q2	$516K	Buy	133,209 +89,405	+204%	+$484K	﹤0.01%	1344
2025 Q1	$219K	Buy	43,804 +29,773	+212%	+$189K	﹤0.01%	953
2024 Q4	$101K	Buy	+14,031	New	+$107K	﹤0.01%	966
2024 Q3	–	Sell	-32,454	Closed	-$216K	–	1117
2024 Q2	$216K	Buy	+32,454	New	+$239K	﹤0.01%	862

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Brevan Howard Capital Management's ALT Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Altimmune (ALT) stake by 31% in Q1 2026, selling an estimated $152K and leaving 78,403 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #1785.

Brevan Howard Capital Management first reported a position in ALT in Q2 2024 and has held it in 7 quarters since. The position peaked at $840K in Q3 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Brevan Howard Capital Management held 78,403 shares of Altimmune worth $241K as of Q1 2026.
Brevan Howard Capital Management sold 35,725 Altimmune shares in Q1 2026, an estimated $152K.
Altimmune made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1785 holding.
Brevan Howard Capital Management first reported a position in Altimmune in Q2 2024 and has held it in 7 quarters since.
Brevan Howard Capital Management's Altimmune position peaked at $840K in Q3 2025.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.